Mi Yeon Jang

Title: Mi Yeon Jang: Innovator in Heteroaryl Compounds

Introduction

Mi Yeon Jang is a prominent inventor based in Gyeonggi-do, South Korea. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of heteroaryl compounds. With a total of 4 patents to her name, her work focuses on innovative solutions for treating diseases related to the Mer tyrosine kinase receptor.

Latest Patents

Her latest patents include groundbreaking inventions such as "Heteroaryl compounds and their use as Mer inhibitors" and "Heteroaryl compounds and their use as therapeutic drugs." The first patent describes compounds of formula (I) that are useful for treating or preventing Mer tyrosine kinase receptor modulated diseases. It also outlines pharmaceutical compositions of these compounds and methods for their application. The second patent provides heterocyclic compounds capable of modulating the activity of Mer receptor tyrosine kinase (MERTK), highlighting their potential as therapeutic agents for cancer and other diseases related to MERTK dysregulation.

Career Highlights

Mi Yeon Jang is currently associated with Dong-a Socio Holdings Co., Ltd., where she continues to advance her research and development efforts. Her work has garnered attention for its potential impact on cancer treatment and other medical applications.

Collaborations

She collaborates with notable colleagues, including Jin Kwan Kim and Hadong Kim, to further enhance the scope and effectiveness of her research.

Conclusion

Mi Yeon Jang's innovative work in the field of heteroaryl compounds positions her as a key figure in pharmaceutical research. Her contributions are paving the way for new therapeutic options in the treatment of diseases linked to MERTK dysregulation.